Saturday 17 October 2026 Export SMMT’s income statement to Excel — free account

Summit Therapeutics PLC

Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00. In the quarter to June 2026, EPS grew 63.2% and free cash flow fell 112.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

14.63 0.74 −4.81%

Follow SMMT

Alert me

Market cap: $12.3B
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 3/9
Altman Z: 0.88
Beneish M: −5.00
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 103.62

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	5	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 80.42%

Capital & Financial Ratios $m

Market Cap 12,260.00

Revenue 0.71

Net Income (856.09)

Free Cash Flow (459.82)

Net Debt (690.99)

Current Ratio 6.96

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 0.00

P/S ratio 16,148.72

P/B ratio 18.07

Past 5Y EPS Growth —

This Y EPS Growth 19.42%

Next Y EPS Growth 2.38%

Next Y revenue growth 38.01%

Next 5Y EPS Growth 21.71%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 79.76%

10-year low 10-year high

P/B against its own 10 years 68.66%

10-year low 10-year high

EV/Sales against its own 10 years 78.77%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	186	413	714	691
Receivables	3	11	7	30
Inventory	—	—	—	—
Other	—	—	—	—
	190	424	720	721

	2023	2024	2025	Q'26
Payables	3	5	20	23
ST’ Debt	—	—	—	—
Other	1	2	2	3
	20	42	73	104

Compound Annual Growth %

	10y	5y	3y
Sales	—	(46.49%)	(1.73%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	52.66%	73.27%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	0	0	0	0	1
’21	0	0	1	0	2
’20	0	0	0	0	1
’19	—	—	0	0	1
’19	—	—	—	—	57
’18	—	—	—	—	16

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(122)	(141)	—	—	—
’25	(61)	(67)	(93)	(102)	(323)
’24	(30)	(33)	(30)	(49)	(142)
’23	(13)	(29)	(15)	(19)	(77)
’22	(19)	(19)	(9)	5	(42)
’21	(21)	(19)	(24)	(9)	(73)
’20	(5)	(19)	(17)	(8)	(48)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(123)	(142)	—	—	—
’25	(62)	(67)	(93)	(102)	(324)
’24	(30)	(33)	(30)	(49)	(142)
’23	(13)	(29)	(15)	(19)	(77)
’22	(19)	(20)	(9)	5	(42)
’21	(21)	(19)	(24)	(9)	(73)
’20	(5)	(19)	(17)	(8)	(49)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.24)	(0.28)	—	—	—
’25	(0.09)	(0.76)	(0.31)	(0.29)	(1.44)
’24	(0.06)	(0.09)	(0.08)	(0.08)	(0.31)
’23	(1.43)	(0.02)	(0.03)	(0.05)	(0.99)
’22	(0.15)	(0.12)	(0.10)	(0.07)	(0.41)
’21	(0.21)	(0.27)	(0.20)	(0.28)	(0.67)
’20	(0.09)	(0.23)	(0.26)	(0.18)	(0.76)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.26	8.24	1.12	1.10	1.18	2.23	0.66	1.25	2.10	15.55	Analyst estimates 2026–2028 Powerpack
	High	19.75	16.86	15.90	2.46	6.14	12.30	5.61	5.78	33.89	36.91
People
People	Employees	37	40	60	61	81	110	77	105	159	265
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.01	0.02	0.01	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	1	3	16	1	1	2	1	—	—	—
	Gross margin, %	0.00	0.00	0.00	100.00	100.00	100.00	100.00	—	—	—
	EBT	(35)	(34)	(31)	(29)	(53)	(89)	(79)	(615)	(221)	(1,080)
	EBT margin, %	(3,925.57)	(1,109.63)	(193.97)	(3,915.34)	(6,152.33)	(4,897.84)	(11,174.75)	0.00	0.00	0.00
	Net income	(31)	(28)	(26)	(29)	(53)	(89)	(79)	(615)	(221)	(1,080)
	Depreciation	0	0	0	2	2	2	3	0	0	0
Per share, $
Per share, $	Revenue	0.01	0.02	0.08	0.02	0.01	0.01	0.00	0.00	0.00	0.00
	Earnings	(0.52)	(0.47)	(0.40)	(0.92)	(0.76)	(0.67)	(0.41)	(0.99)	(0.31)	(1.44)
	Cash flow	(0.15)	0.09	(0.10)	(0.63)	(0.69)	(0.55)	(0.22)	(0.12)	(0.20)	(0.43)
	Capex	0.00	0.00	0.00	(0.01)	(0.01)	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(0.15)	0.09	(0.10)	(0.64)	(0.70)	(0.55)	(0.22)	(0.12)	(0.20)	(0.43)
	Book value	0.13	(0.02)	(0.02)	2.40	1.14	0.63	0.66	0.13	0.54	0.88
	Shares, m	179	187	199	33	70	132	193	620	719	748
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	P/S	0.00	47.96	0.57	92.88	379.96	195.86	1,371.18	—	—	—
	P/B	78.42	6.91	0.52	0.67	4.11	4.25	7.63	—	—	—
	EV/Sales	0.00	34.25	0.06	(19.12)	302.81	156.22	1,152.64	—	—	—
	EV/FCF	2.84	(8.55)	(0.07)	0.23	(5.35)	(3.87)	(19.17)	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(26)	16	(19)	(21)	(48)	(73)	(42)	(77)	(142)	(323)
	Capex	0	0	(1)	0	0	0	(1)	0	0	(1)
	Free cash flow	(26)	16	(19)	(21)	(49)	(73)	(42)	(77)	(142)	(324)
Balance, $m
Balance, $m	Working capital	25	28	19	66	68	72	618	169	382	647
	Total debt	—	—	—	0	0	—	495	100	—	—
	Net debt	(23)	(35)	(29)	(63)	(66)	(72)	(154)	(86)	(413)	(714)
	Shareholders’ equity	23	(4)	(5)	79	79	83	127	78	389	659
Returns, %
Returns, %	ROA	(83.12)	(58.39)	(35.72)	(33.19)	(53.03)	(82.09)	(20.26)	(141.83)	(69.32)	(181.94)
	ROIC	0.00	0.00	0.00	(111.17)	(253.57)	(468.69)	0.00	0.00	0.00	0.00
	ROE	(111.44)	628.29	(630.66)	(43.05)	(66.57)	(108.89)	(75.05)	(601.85)	(94.90)	(206.10)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Dec 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
JAZZ Jazz Pharmaceuticals PLC	$13.9B	13.8×	17.3×	+15.55% (above 0%: growing)	n/m	+140.99% (above 0%: growing)	90.37%	20.54%	Compare
HALO Halozyme Therapeutics, Inc.	$13.8B	34.6×	10.6×	+47.67% (above 0%: growing)	+44.12% (above 0%: growing)	+141.18% (above 0%: growing)	83.54%	59.80%	Compare
BBIO BridgeBio Pharma, Inc.	$13.1B	— (loss-making)	— (loss-making)	+120.39% (above 0%: growing)	n/m	+16.59% (above 0%: growing)	93.83%	(43.94%)	Compare
SMMT Summit Therapeutics PLC	$12.3B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−112.80% (below 0%: shrinking)	0.00%	0.00%
CORT Corcept Therapeutics Incorporated	$12.3B	212×	139×	+31.74% (above 0%: growing)	+21.21% (above 0%: growing)	−29.89% (below 0%: shrinking)	98.41%	16.12%	Compare
TECH Bio-Techne Corp	$11.4B	62.0×	37.6×	+1.33% (above 0%: growing)	n/m	−6.83% (below 0%: shrinking)	65.82%	23.13%	Compare
BMRN BioMarin Pharmaceutical Inc.	$10.9B	144×	16.1×	+19.91% (above 0%: growing)	−81.60% (below 0%: shrinking)	−20.28% (below 0%: shrinking)	79.51%	11.21%	Compare
MDGL Madrigal Pharmaceuticals, Inc.	$10.6B	— (loss-making)	— (loss-making)	+71.17% (above 0%: growing)	n/m	+140.54% (above 0%: growing)	89.02%	(15.46%)	Compare
IBRX ImmunityBio, Inc.	$10.6B	— (loss-making)	— (loss-making)	+93.91% (above 0%: growing)	n/m	+13.38% (above 0%: growing)	99.42%	(120.41%)	Compare
Median of peers	$11.8B	62.0×	17.3×	+39.71%	+21.21%	+14.98%	89.69%	13.67%

All 614 Biotechnology stocks →

Summit Therapeutics PLC (SMMT) key facts

Summit Therapeutics PLC (SMMT) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
As of October 16, 2026, SMMT traded at $14.63, a market capitalization of $12.3 billion.
Return on equity was −206.1% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 0.88 (distress zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.